FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160644013> ?p ?o ?g. }

• W2160644013 endingPage "1156" @default.
• W2160644013 startingPage "1144" @default.
• W2160644013 abstract "The proliferation inhibitor of the macrolide class, everolimus, is a drug shown to be effective in the prevention of organ transplant rejection and to have a potential in the treatment of rheumatoid arthritis and certain cancers. As these diseases or their current treatments are associated with bone loss, we examined the effect of everolimus on mouse and human bone cells in vitro and on bone in an ovariectomized (OVX) rat model. Everolimus potently inhibited primary mouse and human osteoclast activity in the pit assay (IC50 values of 0.6-4.0 nM), as well as osteoclast formation, measured as the number of tartrate-resistant acid phosphatase (TRAP) multinucleated cells (IC50 values of 7.7-10.5 nM). Inhibition of osteoblastic differentiation was also observed (IC50 value of 13.5 nM). As expected, everolimus inhibited proliferation of osteoclast precursors and stimulated apoptosis, albeit with insufficient potency and efficacy to explain inhibition of osteoclast activity. Thus, everolimus appeared to directly inhibit bone resorption, which is in accord with the detected inhibition of mRNA and protein expression of cathepsin K; the main collagen-degrading protease in osteoclasts. Despite the in vitro antiproliferative activity of everolimus and the observed inhibition of osteoblast differentiation, no detrimental effects were detected at different skeletal sites in mature OVX rats at doses up to 3 mg/kg/day. This everolimus dose also prevented the OVX-induced loss of cancellous bone by 60%, an effect predominantly associated with decreased osteoclast-mediated bone resorption, resulting in a partial preservation of the cancellous bone network. Everolimus inhibited S6 kinase 1 activity in rat blood cells, skin, and bone, at doses equivalent to those used for efficacy experiments in the OVX rat model, which demonstrated in vivo targeting of the expected molecular pathway. In conclusion, everolimus directly inhibits bone resorption by osteoclasts and thus could at least be neutral or protective for bone in vivo, which would favor its use in disease indications associated with bone loss." @default.
• W2160644013 created "2016-06-24" @default.
• W2160644013 creator A5005084447 @default.
• W2160644013 creator A5011100499 @default.
• W2160644013 creator A5030178833 @default.
• W2160644013 creator A5047606933 @default.
• W2160644013 creator A5052164166 @default.
• W2160644013 creator A5068225193 @default.
• W2160644013 creator A5072610921 @default.
• W2160644013 creator A5082438939 @default.
• W2160644013 creator A5087726605 @default.
• W2160644013 date "2004-11-01" @default.
• W2160644013 modified "2023-10-17" @default.
• W2160644013 title "Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts" @default.
• W2160644013 cites W1489003564 @default.
• W2160644013 cites W1560301770 @default.
• W2160644013 cites W1573842875 @default.
• W2160644013 cites W1965976637 @default.
• W2160644013 cites W1966287849 @default.
• W2160644013 cites W1967492863 @default.
• W2160644013 cites W1967502057 @default.
• W2160644013 cites W2002199578 @default.
• W2160644013 cites W2004190331 @default.
• W2160644013 cites W2012888463 @default.
• W2160644013 cites W2017614987 @default.
• W2160644013 cites W2022140268 @default.
• W2160644013 cites W2026351725 @default.
• W2160644013 cites W2039614896 @default.
• W2160644013 cites W2047380663 @default.
• W2160644013 cites W2048814899 @default.
• W2160644013 cites W2064260521 @default.
• W2160644013 cites W2072057417 @default.
• W2160644013 cites W2074929219 @default.
• W2160644013 cites W2083933327 @default.
• W2160644013 cites W2084152511 @default.
• W2160644013 cites W2084535197 @default.
• W2160644013 cites W2087378917 @default.
• W2160644013 cites W2089668045 @default.
• W2160644013 cites W2093147348 @default.
• W2160644013 cites W2095481713 @default.
• W2160644013 cites W2102460328 @default.
• W2160644013 cites W2120129511 @default.
• W2160644013 cites W2142364508 @default.
• W2160644013 cites W2157717388 @default.
• W2160644013 cites W2157973267 @default.
• W2160644013 cites W2169791814 @default.
• W2160644013 cites W4232156511 @default.
• W2160644013 doi "https://doi.org/10.1016/j.bone.2004.07.013" @default.
• W2160644013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15542040" @default.
• W2160644013 hasPublicationYear "2004" @default.
• W2160644013 type Work @default.
• W2160644013 sameAs 2160644013 @default.
• W2160644013 citedByCount "142" @default.
• W2160644013 countsByYear W21606440132012 @default.
• W2160644013 countsByYear W21606440132013 @default.
• W2160644013 countsByYear W21606440132014 @default.
• W2160644013 countsByYear W21606440132015 @default.
• W2160644013 countsByYear W21606440132016 @default.
• W2160644013 countsByYear W21606440132017 @default.
• W2160644013 countsByYear W21606440132018 @default.
• W2160644013 countsByYear W21606440132019 @default.
• W2160644013 countsByYear W21606440132020 @default.
• W2160644013 countsByYear W21606440132021 @default.
• W2160644013 countsByYear W21606440132022 @default.
• W2160644013 countsByYear W21606440132023 @default.
• W2160644013 crossrefType "journal-article" @default.
• W2160644013 hasAuthorship W2160644013A5005084447 @default.
• W2160644013 hasAuthorship W2160644013A5011100499 @default.
• W2160644013 hasAuthorship W2160644013A5030178833 @default.
• W2160644013 hasAuthorship W2160644013A5047606933 @default.
• W2160644013 hasAuthorship W2160644013A5052164166 @default.
• W2160644013 hasAuthorship W2160644013A5068225193 @default.
• W2160644013 hasAuthorship W2160644013A5072610921 @default.
• W2160644013 hasAuthorship W2160644013A5082438939 @default.
• W2160644013 hasAuthorship W2160644013A5087726605 @default.
• W2160644013 hasConcept C101990758 @default.
• W2160644013 hasConcept C126322002 @default.
• W2160644013 hasConcept C134018914 @default.
• W2160644013 hasConcept C142724271 @default.
• W2160644013 hasConcept C146562846 @default.
• W2160644013 hasConcept C167844969 @default.
• W2160644013 hasConcept C181199279 @default.
• W2160644013 hasConcept C185592680 @default.
• W2160644013 hasConcept C202751555 @default.
• W2160644013 hasConcept C2776033226 @default.
• W2160644013 hasConcept C2776350087 @default.
• W2160644013 hasConcept C2778260815 @default.
• W2160644013 hasConcept C2779699572 @default.
• W2160644013 hasConcept C55493867 @default.
• W2160644013 hasConcept C673006 @default.
• W2160644013 hasConcept C71924100 @default.
• W2160644013 hasConcept C98274493 @default.
• W2160644013 hasConceptScore W2160644013C101990758 @default.
• W2160644013 hasConceptScore W2160644013C126322002 @default.
• W2160644013 hasConceptScore W2160644013C134018914 @default.
• W2160644013 hasConceptScore W2160644013C142724271 @default.
• W2160644013 hasConceptScore W2160644013C146562846 @default.
• W2160644013 hasConceptScore W2160644013C167844969 @default.

• next